FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Glenmark Pharmaceuticals Theophylline Recall

Theophylline (Anhydrous) Extended-Release Tablets, 600 mg, 100 Tablets per bottle, Rx O…

Glenmark Pharmaceuticals Inc., USA · Mahwah, NJ

Risk level
Class II
Reported by FDA
Jun 4, 2025
Recall ID
D-0452-2025
Check your lot numberHow we source this data

Summary

Glenmark Pharmaceuticals recalled Theophylline starting May 15, 2025. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0452-2025 on Jun 4, 2025. Reason: OOS results reported for the Dissolution (by UV) test. Status: Ongoing.

Why it was recalled

OOS results reported for the Dissolution (by UV) test.

Product description

Theophylline (Anhydrous) Extended-Release Tablets, 600 mg, 100 Tablets per bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited. Colvale-Bardez, Goa - 403513, India. Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430. NDC: 68462-356-01

Lot numbers, UPCs & expiration codes

Lots: 19234121, 19234148, Exp Sep-30-25; Lots 19242881, 19242899, Exp Jun-30-26

Where it was sold

Nationwide in the USA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0452-2025
Classification
Class II
Status
Ongoing
Recall initiated
May 15, 2025
FDA report date
Jun 4, 2025
Quantity
8,520 100-count bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Glenmark Pharmaceuticals Inc., USA

Original FDA data

Every field from FDA enforcement report D-0452-2025, exactly as published.

Show all FDA fields
City
Mahwah
State
NJ
Status
Ongoing
Country
United States
Event ID
96867
Address
750 Corporate Dr
Code information
Lots: 19234121, 19234148, Exp Sep-30-25; Lots 19242881, 19242899, Exp Jun-30-26
Postal code
07430-2009
Report date
Jun 4, 2025
Product type
Drugs
Recall number
D-0452-2025
Classification
Class II
Recalling firm
Glenmark Pharmaceuticals Inc., USA
Product quantity
8,520 100-count bottles
Reason for recall
OOS results reported for the Dissolution (by UV) test.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Theophylline (Anhydrous) Extended-Release Tablets, 600 mg, 100 Tablets per bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited. Colvale-Bardez, Goa - 403513, India. Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430. NDC: 68462-356-01
Distribution pattern
Nationwide in the USA
Recall initiation date
May 15, 2025
Initial firm notification
Letter
Center classification date
May 28, 2025

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0452-2025, published Jun 4, 2025. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls